CD7 CAR-T cell therapy for T-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called CD7 CAR-T that targets a specific protein on your cancer cells. It is for people with T-cell lymphoma or T-cell leukemia that has not responded to other treatments or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of T-cell cancer (lymphoma or leukemia) that has come back after treatment or hasn't responded to at least two standard treatments.
- Your cancer cells have a specific marker called CD7 on their surface.
- You are between 14 and 75 years old.
- You are generally healthy enough to be up and active for most of the day (ECOG score 0-2).
- Your blood counts, kidney, liver, and heart function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells (CAR-T) engineered to find and attack CD7 on T-cell lymphoma cells, followed by a stem cell transplant to rebuild your immune system. It is for people with certain types of T-cell lymphoma that have come back or not responded to standard treatments.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Hear when a new CD7+ Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.